BioCentury
ARTICLE | Company News

Biogen, Columbia University, The ALS Association deal

October 5, 2015 7:00 AM UTC

Biogen, the university’s medical center and the association partnered to use next-generation sequencing and clinical phenotyping to identify genetic risk factors in 1,500 patients with amyotrophic lateral sclerosis. The project, titled Genomic Translation for ALS Clinical care (GTAC), aims to develop individually tailored therapies. Biogen will have exclusive rights to data generated from the deal to develop therapeutics. ...